Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Parameters

NCT05552508 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05552508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Parameters
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 11, 2022
Completion date
July 19, 2024
Enrollment
45 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

asthma